Innoblative Designs announced today that it received FDA breakthrough device designation for its SIRA RFA electrosurgical device. Chicago-based Innoblative Designs designed SIRA for use in breast cancer patients undergoing BCS (lumpectomy). The company plans to present data supporting its breakthrough nod this week. It’s presenting at the Annual Meeting for The American Society of Breast […]
Oncology
RenovoRx appoints new SVP of clinical operations
RenovoRx (Nasdaq:RNXT) announced today that it appointed Leesa Gentry as senior vice president of clinical operations. Los Altos, California-based RenovoRx said Gentry brings with her “valuable leadership experience” to advance the company’s cancer treatment studies. She becomes the fourth addition to the company’s executive management team in the last year. That group includes COO Angela […]
Illumina to appeal FTC decision on Grail acquisition, aims for resolution by 2024
Illumina (Nasdaq:ILMN) announced today that it plans to appeal the Federal Trade Commission’s (FTC) decision over its acquisition of Grail. The FTC today announced that it finds the $7.1 billion acquisition “likely to substantially reduce competition” in the U.S. It would affect the research, development and commercialization of cancer tests, FTC said. In its decision, […]
HistoSonics announces first kidney tumor treatment with histotripsy
HistoSonics announced the treatment of the first kidney patient using the company’s histotripsy platform in the United Kingdom. Professor Tze Min Wah, senior consultant radiologist and clinical lead for the interventional oncology program at Leeds Teaching Hospitals NHS Trust, performed the procedure. It marks the initial treatment in HistoSonics’ sponsored “CAIN” trial. The Phase I […]
iCad lays off 28% of its workforce in restructuring plan
iCad (Nasdaq:ICAD) announced that it enacted a restructuring plan that includes a workforce reduction of approximately 28%. The Nashua, New Hampshire-based cancer detection and therapy solution developer said that equates to approximately 23 employees. It attributed the restructuring plan to ongoing industry and macroeconomic pressures. iCad’s restructuring aims to support long-term strategic goals and reduce operating […]
Studies back skin cancer detection device from DermaSensor
DermaSensor today presented data from two clinical studies supporting its non-invasive device for evaluating suspicious skin lesions. Miami, Florida-based DermaSensor’s handheld device uses a form of optical spectroscopy called elastic scattering spectroscopy (ESS). It takes noninvasive samples of tissue, capturing cellular-level information. The technology uses hundreds of wavelengths of light in a manner similar to […]
Elekta forms radiotherapy partnership with Sinopharm in China
Elekta announced today that it entered into a joint venture with Sinopharm to increase the adoption of radiation therapy in China. The initiative aims to bring radiation therapy to what’s considered lower-tier cities. These cities comprise approximately 70% of China’s population, according to a news release. Elekta develops precision radiation therapy to treat cancer. The […]
iCad CEO Stacey Stevens resigns for personal reasons, Dana Brown named as replacement
iCad (Nasdaq:ICAD) announced today that it accepted the resignation — for personal reasons — of Stacey Stevens as president and CEO. Stevens, who took over the corner office in March 2022, plans to remain with the company through April 30, 2023. She intends to ensure a smooth transition to new president and CEO, Dana Brown. […]
Study supports RenovoRx drug-device combo for treating pancreatic cancer
RenovoRx (Nasdaq:RNXT) today announced promising interim data for its RenovoGem drug-device combination for treating pancreatic cancer. The Tiger-Pac clinical trial investigates RenovoGem as a potential treatment option in locally advanced pancreatic cancer (LAPC). Interim data from the Phase III open-label study suggests a six-month potential improvement in median overall survival with RenovoGem. RenovoGem utilizes the […]
FDA clears Elekta’s radiation therapy automation
Elekta (Stockholm:EKTA-B) says an FDA 510(k) clearance represents a new era in precision radiation therapy to treat cancer in the U.S. The Sweden-based cancer and brain treatment tech company announced today that the FDA has cleared Comprehensive Motion Management (CMM) with True Tracking and automatic gating. The features are part of Elekta’s Unity MR-Linac radiotherapy […]
Novocure stock dips on Q4 EPS miss
Novocure (Nasdaq:NVCR) shares took a hit today on fourth-quarter results that came in mixed compared to the consensus forecast. Shares of NVCR dipped 4.6% at $78.26 apiece in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 8.1%. The Root, Switzerland-based tumor-treating fields developer […]